3児の親さん薬剤師のブログ

とある薬剤師です。感染症治療を考える素材をちょこっと提供。noteもあります https://note.com/twin1980

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa

CIDに報告された、耐性緑膿菌感染症に対する、Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimensのレトロ

 

academic.oup.com

 

感想 まとめ

 

レトロですが、Ceftolozane/tazobactamとPolymyxin or Aminoglycoside-based Regimensは、死亡率に差がなかった研究。

 

AKIや臨床治癒は、Ceftolozane/tazobactamが良さそうですが、カネとかどうなのか?

 

 

Abstract


Background
Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains activity against resistant Pseudomonas aeruginosa. The comparative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown.

 

Methods

A retrospective, multicenter, observational cohort study was performed. Patients who received ceftolozane/tazobactam were compared with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug-resistant P. aeruginosa. Multivariate logistic regression was performed controlling for factors associated with treatment to assess the independent impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospital mortality.

 

Results

A total of 200 patients were included (100 in each treatment arm). The cohort represented an ill population with 69% in the intensive care unit, 63% mechanically ventilated, and 42% in severe sepsis or septic shock at infection onset. The most common infection type was ventilator-associated pneumonia (52%); 7% of patients were bacteremic. Combination therapy was more commonly used in polymyxin/aminoglycoside patients than those who received ceftolozane/tazobactam (72% vs 15%, P < .001). After adjusting for differences between groups, receipt of ceftolozane/tazobactam was independently associated with clinical cure (adjusted odds ratio [aOR], 2.63; 95% confidence interval [CI], 1.31–5.30) and protective against AKI (aOR, 0.08; 95% CI, 0.03–0.22). There was no difference in in-hospital mortality. The number needed to treat for a clinical cure with ceftolozane/tazobactam was 5, and the number needed to harm with AKI with a polymyxin/aminoglycoside was 4.

 

Conclusions

These data support the preferential use of ceftolozane/tazobactam over polymyxins or aminoglycosides for drug-resistant P. aeruginosa infections.

 

 

日本語版 サンフォード感染症治療ガイド2019(第49版)

日本語版 サンフォード感染症治療ガイド2019(第49版)

  • 作者: 菊池賢,橋本正良,M.D. David N. Gilbert,M.D. Henry F.Chambers,M.D. George M. Eliopoulos,M.D. Michael S. Saag,M.D. Andrew T. Pavia
  • 出版社/メーカー: ライフサイエンス出版
  • 発売日: 2019/07/07
  • メディア: 単行本
  • この商品を含むブログを見る